Effects of TGF-β on the immune system: Implications for cancer immunotherapy

Leukemia

Volumn 13, Issue 8, 1999, Pages 1188-1199

  De Visser, K E ^a   Kast, W M ^a,b  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cancer immunotherapy; Immunosuppression; Leukemia; TGF

Indexed keywords

ALPHA 2 MACROGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 2; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032868805     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401477     Document Type: Review

References (152)

1. Kingsley DM. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev 1994; 8: 133-146.
2. Alevizopoulos A, Mermod N. Transforming growth factor-β: the breaking open of a black box. Bio Essays 1997; 19: 581-591.
3. Roberts AB, Kim SJ, Noma T, Glick AB, Lafyatis R, Lechleider R, Jakowlew SB, Geiser A, O'Reilly MA, Danielpour D. Multiple forms of TGF-beta: distinct promoters and differential expression. Ciba Found Symp 1991; 157: 7-15.
4. Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987; 84: 6020-6024.
5. Blanckaert VD, Schelling ME, Elstad CA, Meadows GG. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res 1993; 53: 4075-4081.
6. Doran T, Stuhlmiller H, Kim JA, Martin EW Jr, Triozzi PL. Oncogene and cytokine expression of human colorectal tumors responding to immunotherapy. J Immunother 1997; 20: 372-376.
7. Romieu R, Lacabanne V, Kayibanda M, Antoine B, Bennoun M, Chouaib S, Guillet JG, Viguier M. Critical stages of tumor growth regulation in transgenic mice harboring a hepatocellular carcinoma revealed by distinct patterns of tumor necrosis factor-β and transforming growth factor-β mRNA production. Int Immunol 1997; 9: 1405-1413.
8. Vánky F, Nagy N, Hising C, Sjovall K, Larson B, Klein E. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 1997; 42: 317-323.
9. Picon A, Gold LI, Wang J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor betal. Cancer Epidemiol Biomarkers Prev 1998; 7: 497-504.
10. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor betal is associated with angiogenesis, metastasis, and poor clinical outcome in protstate cancer. Prostate 1998; 37: 19-29.
11. Nunes I, Gleizes PE, Metz CN, Rifkin DB. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 1997; 136: 1151-1163.
12. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 1997; 51: 1376-1382.
13. LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated α2-macroglobulins. Lab Invest 1991; 65: 3-14.
14. Letterio JJ, Roberts AB. TGF-β: a critical modulator of immune cell function. Clin Immunol Immunopathol 1997; 84: 251-259.
15. Munger JS, Huang X, Kawakatsu H, Griffiths MJD, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D. The integrin αvβ6 binds and activates latent TFGβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328.
16. Schultz-Cherry S, Ribeiro S, Gentry L, Murphy-Ullrich JE. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in chemically defined system. J Biol Chem 1994; 269: 26775-26782.
17. Takiuchi H, Tada T, Li XF, Ogata M, Ikeda T, Fujimoto S, Fujiwara H, Hamaoka T. Particular types of tumour cells have the capacity to convert transforming growth factor β from a latent to an active form. Cancer Res 1992; 52: 5641-5646.
18. Horimoto M, Kato J, Takimoto R, Terui T, Mogi Y, Niitsu Y. Identification of a transforming growth factor beta-1 activator derived from a human gastric cancer cell line. Br J Cancer 1995; 72: 676-682.
19. Yingling JM, Wang XF, Bassing CH. Signaling by the transforming growth factor-β receptors. Biochim Biophys Acta 1995; 1242: 115-136.
20. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997; 18: 493-497.
21. Heldin CH, Myazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
22. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and undergo homo-and hetero-oligomerization upon activation by serine/threonine kinase receptors. EMBO J 1998; 17: 4056-4065.
23. Zhang Y, Feng X-H, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription. Nature 1998; 394:909-913.
24. Imamura T, Takase M, Nishihara A, Oeda E, Hanai JI, Kawabata M, Miyazono K. Smad6 inhibits signalling by the TGF-β superfamily. Nature 1997; 389: 622-626.
25. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996; 383: 832-836.
26. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1998; 1: 611-617.
27. Bruno E, Horrigan SK, van den Berg D, Rozler E, Fitting PR, Moss ST, Westbrook C, Hoffman R. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 1998; 91: 1917-1923.
28. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massagué J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 1990; 62: 175-185.
29. Planas-Silva MD, Weinberg RA. The restriction point and control of cell proliferation. Curr Opin Cell Biol 1997; 9: 768-772.
30. Ando K, Griffin JD. Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. Oncogene 1995; 10: 751-755.
31. INK4B B cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol 1997; 17: 2458-2467.
32. Coffey RJ, Bascom CC, Sipes NJ, Graves-Deal R, Weissman BE, Moses HL. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor β. Mol Cell Biol 1988; 8: 3088-3093.
33. Takehara K, LeRoy EC, Grotendorst GR. TGF-β inhibition of endothelial cell proliferation: alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expression. Cell 1987; 49: 415-422.
34. Heinrich MC, Dooley DC, Keeble WW. Transforming growth factor b1 inhibits expression of the gene products for steel factor and its receptor (c-kit). Blood 1995; 85: 1769-1780.
35. Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S, Wahl SM. Immune dysregulation in TGF-beta 1-deficient mice. J Immunol 1994; 153: 1936-1946.
36. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699.
37. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-774.
38. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derunck R, Sporn MB, Fauci AS. Production of transforming growth factor β by human T-lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 1986; 163: 1037-1050.
39. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 1987; 166: 991-998.
40. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li XF, Shimizu J, Fujiwara H, Hamaoka T. Transforming growth factor-β-induced inhibition of T cell function. J Immunol 1991; 146: 1077-1082.
41. McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM. Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother 1994; 15: 155-164.
42. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC. Regulation of lymphockine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-β. J Immunol 1991; 146: 3289-3297.
43. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995; 21: 128-151.
44. Genestier L, Kasibhatla S, Brunner T, Green DR. Transforming growth factor β1 inhibits fas ligand expression and subsequent activation-induced cell death in T cels via downregulation of c-Myc. J Exp Med 1999; 189: 231-239.
45. Lee HM, Rich S. Differential activation of CD8+ T cells by transforming growth factor-beta 1. J Immunother 1993; 151: 668-677.
46. Inge TH, Hoover SK, Susskind BM, Barett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor b1. Cancer Res 1992; 52: 1386-1392.
47. Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA. inhibition of cytokine production by cyclosporin-A and transforming growth factor-beta. J Exp Med 1987; 166: 571-576.
48. Ahuja SS, Paliogianni F, Yamada H, Balow JE, Boumpas DT. Effect of transforming growth factor-β on early and late activation events in human T cells. J Immunol 1993; 150: 3109-3118.
49. Stoeck M, Miescher S, MacDonald HR, von Fliedner V. Transforming growth factor beta slow down cell-cycle progression in a murine interleukin 2-dependent T-cell line. J Cell Physiol 1989; 141: 65-73.
50. Ristow HJ. BSC-1 growth inhibitor/type beta transforming growth factor is a strong inhibitor of thymocyte proliferation. Proc Natl Acad Sci USA 1986; 83: 5531-5533.
51. Weller M, Constam DB, Malipiero U, Fontana A. Transforming growth factor-β2 induces apoptosis of murine T cell clone without down-regulating bcl-2 mRNA expression. Eur J Immunol 1994; 24: 1293-1300.
52. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-β on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 1988; 141: 690-698.
53. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature 1999; 397: 710-713.
54. Pardoux C, Ma X, Gobert S, Pellegrini S, Mayeux P, Gay F, Trinchieri G, Chouaib S. Downregulation of interleukin-12 responsiveness in human T cells by transforming growth factor-β: relationship with IL-12 signaling. Blood 1999; 93: 1448-1455.
55. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ, Keller JR. Transforming growth factor b is a potent inhibitor of interleukin 1 (IL-1) receptor expression: Proposed mechanism of inhibition of IL-1 action. J Exp Med 1990; 172: 737-744.
56. Sykora KW, Tomeczkowski J, Reiter A. C-kit receptors in childhood malignant lymphoblastic cells. Leuk Lymphoma 1997; 25: 201-216.
57. Tomeczkowski J, Frick D, Schwinzer B, Wittner M, Ludwig WD, Reiter A, Weite K, Sykora KW. Expression and regulation of c-kit receptor and response to stem cell factor in childhood malignant T-lymphoblastic cells. Leukemia 1998; 12: 1221-1229.
58. Dubois CM, Ruscetti FW, Stankova J, Keller JR. Transforming growth factor-b regulates c-kit message stability and cell surface protein expression in hematopoietic progenitors. Blood 1994; 83: 3138-3145.
59. Begley CG, Nicola NA. Resolving conflicting signals: cross inhibition of cytokine signaling pathways. Blood 1999; 93: 1443-1447.
60. Walunas T, Lenschow D, Bakker C, Linsley P, Freeman G, Green J, Thompson C, Bluestone J. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
61. Krummel M, Allison J. CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
62. Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor b (TGF-b) production by murine CD4+ T cells. J Exp Med 1998; 188: 1849-1857.
63. Espevik T, Figari IS, Ranges GE, Palladino MA. Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokine-activated killer cell activity: comparison between natural porcine platelet-derived TGF-β1, and TGF-β2, and recombinant human TGF-β1. J Immunol 1988; 140: 2312-2316.
64. Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, Shiraishi A. TGF-β enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J Immunol 1995; 155: 4926-4932.
65. Borkowski TA, Letterio JJ, Farr AG, Udey MC. A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med 1996; 184: 2417-2422.
66. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, Amigorena S, Hermine O, Durandy A. TFG-β1 prevents the noncognate maturation of human dendritic langerhans cells. J Immunol 1999; 162: 4567-4575.
67. Bouchard C, Frikman WH, Sautès C. Effect of TGF-β1 on cell-cycle regulatory proteins in LPS-stimulated normal mouse B lymphocytes. J Immunol 1997; 159: 4155-4164.
68. Shieh JJ, Tseng J. Induction of B cell IgA secretion by the culture supernatants of lipopolysaccharide-stimulated peritoneal macrophages. Proc Natl Acad Sci Council, Republic of China-Part B, Life Sciences 1994; 18: 17-23.
69. Chen J-J, Sun Y, Nabel CJ. Regulation of the proinflammatory effects of Fas Ligand (CD95L). Science 1998; 282: 1714-1717.
70. Czarniecki CW, Chiu HH, Wong GHW, McCabe SM, Palladino MA. Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol 1988: 140: 4217-4223.
71. Keller JR, Mantel C, Sing GK, Ellingsworth LR, Ruscetti SK, Ruscetti FW. Transforming growth factor β1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines. J Exp Med 1988; 168: 737-750.
72. Sitnicka E, Ruscetti FW, Priestley GV, Wolf NS, Bartelmez SH. Transforming growth factor β1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 1996; 88: 82-88.
73. Goey H, Keller JR, Back T, Longo DL, Ruscetti FW, Wiltrout RH. Inhibition of early murine hematopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-β1. J Immunol 1989; 143: 877-880.
74. Terui T, Niitsu Y, Mahara K, Fujisaki Y, Urushizaki Y, Mogi Y, Kohgo Y, Watanabe N, Ogura M, Saito H. The production of transforming growth factor-b in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 1990; 7: 1540-1548.
75. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor b as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994; 179: 999-1004.
76. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME. Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 5877-5881.
77. Tessier N, Hoang T. Transforming growth factor b inhibits the proliferation of the blast cells of acute myeloblastic leukemia. Blood 1988; 72: 159-164.
78. Taetle R, Payne C, Dod Santos B, Russell M, Segarini P. Effects of transforming growth factor β1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res 1993; 53: 3386-3393.
79. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-β. Blood 1997; 89: 941-947.
80. Buske C, Becker D, Feuring-Buske M, Hannig H, Wulf G, Schäfer C, Hiddemann W, Wörmann B. TGF-β inhibits growth and induces apoptosis in leukemic B cell precursors. Leukemia 1997; 11: 386-392.
81. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 1997; 57: 832-836.
82. INK4b gene in myelodysplastic syndrome is frequent and acquired during disease pregression. Blood 1998; 91: 2985-2990.
83. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1a, is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood 1998; 92: 2338-2344.
84. Ikezoe T, Takeuchi S, Kamioka M, Daibata M, Kubonishi I, Taguchi H, Miyoshi I. Analysis of the Smad2 gene in hematological malignancies. Leukemia 1998; 12: 94-95.
85. Wieser R, Gruber B, Rieder H, Fonatsch C. Mutational analysis of the tumor suppressor Smad2 in acute lymphoid and myeloid leukemia. Leukemia 1998; 12: 1114-1118.
86. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 1999; 18: 1280-1291.
87. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TFG-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1. Leukemia 1999; 13: 348-357.
88. Kanatani Y, Kasukabe T, Okabe-Kado J, Hayashi S-I, Yamamoto-Yamaguchi Y, Motoyoshi K, Nagata N, Honma Y. Transforming growth factor b and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of human monocytoid leukemia cells. Cell Growth Differ 1996; 7: 187-196.
89. Falk LA, De Benedetti F, Lohrey N, Birchenall-Roberts MC, Ellingsworth LW, Faltynek CR, Ruscetti FW. Induction of transforming growth factor-b1 (TGF-b1) receptor expression and TGF-β1 protein production in retinoic acid-treated HL-60 cells: possible TGF-β1-mediated autocrine inhibition. Blood 1991; 77: 1248-1255.
90. Giralt SA, Kolb HJ. Donor lymphocyte infusions. Curr Opin Oncol 1996; 8: 96-102.
91. Barrett, Malkovska V. The graft-versus-leukemia effect. Curr Opin Oncol 1996; 8: 89-95.
92. Kolb HF, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9: 139-145.
93. Porter DL, Antin JH. Infusion of donor peripheral blood mono-nuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. Hematol Oncol Clin N Am 1998; 12: 123-150.
94. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997; 20: 129-135.
95. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290-2296.
96. Ostankovitch M, Buzyn A, Bonhomme D, Connan F, Bouscary D, Heshmati F, Dreyfus F, Choppin J, Guillet JG. Antileukemic HLA-restricted T-cell clones generated with naturally processed peptides eluted from acute myeloblastic leukemia blasts. Blood 1998; 92: 19-24.
97. Dunussi-Joannopoulos D, Dranoff G, Weinstein HJ, Ferrara JL, Bierer EE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998; 91: 222-230.
98. Vos de S, Kohn DB, Cho SK, McBride WH, Said JW, Koeffler HP. Immunotherapy against murine leukemia. Leukemia 1998; 12: 401-405.
99. Velders MP, Schreiber H, Kast WM. Active immunization against cancer cells: impediments and advances. Semin Oncol 1998; 25: 697-706.
100. Kast WM, Schreiber H, Velders MP. Tumour immunology, Encyclopedia of Life Sciences. Macmillan Reference Ltd 1999, in press.
101. Davies M, Prime SS, Stone AM, Heung YLM, Huntley SP, Matthews JB, Eveson JW, Paterson IC. Overexpression of autocrine TGF-β1 suppresses the growth of spindle epithelial cells in vitro and in vivo in the rat 4NQO model of oral carcinogenesis. Int J Cancer 1997; 73: 68-74.
102. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV. Inactivation of the Type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-1338.
103. Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998; 4: 1625-1630.
104. Kekow J, Wiedemann G. Transforming growth factor β: a cytokine with multiple actions in oncology and potential clinical applications. Int J Oncol 1995; 7: 177-182.
105. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L. MADR2 maps to 18q21 and encloses a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86: 543-552.
106. Sun P, Dong P, Dai K, Hannon GJ, Beach D. p53-independent role of MDM2 in TGF-β1 resistance. Science 1998; 282: 2270-2272.
107. Ueki N, Nakazato M, Ohkawa T, Ikeda T, Amuro Y, Hada T, Higashino K. Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim Biophys Acta 1992; 1137: 189-196.
108. O'Mahony CA, Albo D, Tuszynski GP, Berger DH. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells. Surgery 1998; 124: 388-393.
109. Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-beta. Am Rev Resp Dis 1989; 140: 1126-1128.
110. Haralson MA. Transforming growth factor-β, other growth factors, and the extracellular matrix. J Lab Clin Med 1997; 130: 455-458.
111. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87: 1486-1490.
112. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, lmomukai SH, Nomura Y, Matsuda Y, Matsuzawa Y. High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroent 1996; 110: 375-382.
113. Wunderlich H, Steiner T, Kosmehl H, Junker U, Reinhold D, Reichelt O, Zermann DH, Schubert J. Increased transforming growth factor betal plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol Int 1998; 60: 205-207.
114. Constam DB, Philipp J, Malipiero UV, Ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-β1, β2 and β3 by glioblastoma cells, astrocytes and microglia. J Immunol 1992; 148: 1404-1410.
115. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dörries R, Schlingensiepen KH, Brysch W. The effect of transforming growth factor-β2-specific phosphorothioate-antisense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 1993; 78: 944-951.
116. Mahaley MS, Bertsch L, Cush S, Gillespie GY. Systemic gamma-interferon therapy for recurrent gliomas. J Neurosurg 1988; 70: 826-829.
117. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 1989; 70: 175-182.
118. Lillehei KO, Mitchell DH, Johnson SP, McCleary EL, Kruse CA. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 1991; 28: 16-23.
119. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991; 12: 370-374.
120. Elliott CH, Brooks W, Roszman T. Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J Natl Cancer Inst 1987; 78: 919-922.
121. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997; 20: 165-177.
122. Huber D, Philipp J, Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol 1992; 148: 277-284.
123. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 1985; 313: 1485-1492.
124. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 1988; 319: 1676-1680.
125. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Lobol RE. Eradication of established intracranial rat gliomas by transforming growth factor β antisense therapy. Proc Natl Acad Sci USA 1996; 93: 2909-2914.
126. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM, Kast WM. Vaccination with cytotoxic T lymphocyte epitope-cortaining peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-2249.
127. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJM, Ildstad ST, Kast WM, DeLeo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995; 1: 1297-1302.
128. Da Silva DM, Velders MP, Rudolf MP, Schiller JT, Kast WM. Papillomavirus virus-like particles as anticancer vaccines. Curr Opin Mol Therap 1999; 1: 82-88.
129. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996; 14: 1485-1494.
130. Schirmbeck R, Böhm W, Reimann J. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J Immunol 1996; 157: 3550-3558.
131. Jahn B, Brieger J, Fenchel K, Mitrou S, Berhamnn L. In vivo regulation of transforming growth factor β1 transcription by immunotherapy: interleukin-2 impairs interferon-α-stimulated increase in steady-state mRNA levels of transforming growth factor β1. Cancer Immunol Immunother 1994; 38: 304-310.
132. Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E. Transforming growth factor β1 (TGF-β1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF-β1 antisense expression plasmid. Cell Growth Differ 1995; 6: 1635-1642.
133. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997; 57: 3200-3207.
134. Wu SP, Sun LZ, Willson JKV, Humphrey L, Kerbel R, Brattain MG. Repression of autocrine transforming growth factor β1 and β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ 1993; 4: 115-123.
135. Yuan L, Kuramitsu Y, Li Y, Kobayashi M, Hosokawa M. Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin. Cancer Immunol Immunother 1995; 41: 355-362.
136. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity: implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993; 92: 2569-2576.
137. Arteaga CL, Carty-Dugger T, Moses H, Hurd S, Pietenpol J. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993; 4: 193-201.
138. Hoefer M, Anderer FA. Anti-(transforming growth factor-beta) antibodies with predefined specificity inhibit metastasis of higher tumorigenic human xenotransplants in nu/nu mice. Cancer Immunol Immunother 1995; 41: 302-308.
139. Wojtowicz-Praga S, Verma UM, Wakefield L, Esteban JM, Hartmann D, Mazumber A. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor β antibody and interleukin-2. J Immunother 1996; 19: 169-175.
140. Gonas SL, Pizzo SV. Conformation and protease binding-activity of binary and ternary human α2-macroglobulin-protease complexes. J Biol Chem 1983; 258: 14682-14685.
141. Sottrup-Jensen L. α-Macroglobulins, structure, shape and mechanism of proteinase complex formation. J Biol Chem 1989; 264: 11539-11542.
142. LaMarre J, Hayes MA, Wollenberg GK, Hussaini I, Hall SW, Gonias SL. An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J Clin Invest 1991; 87: 39-44.
143. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (P75)-Fc fusion protein. New Engl J Med 1997; 337: 141-147.
144. Weiskirch LM, Bar-Dagan Y, Modyr MB. Transforming growth factor-β-mediated down-regulation of anti-tumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following melphalan therapy. Cancer Immunol Immunother 1994; 38: 215-235.
145. Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense ligonucleotides. Clin Pharmacokinet 1995; 28: 7-16.
146. Rensen PCN, De Vrueh RLA, Van Berkel TJC. Targeting hepatitis B therapy to the liver. Clin Pharmacokinet 1996; 31: 131-155.
147. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-1142.
148. Blottiere HM, Steplewski Z, Herlyn D, Douillard JY. Human anti-murine immunoglobulin responses and immune function in cancer patients receiving murine monoclonal antibody therapy. Hum Antibodies Hybridomas 1991; 2: 16-25.
149. Grossbard ML, Press OW, Applebaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863-878.
150. Greenaway S, Henniker AJ, Walsh M, Bradstock KF. A pilot clinical trial of two murine monoclonal antibodies fixing human complement in patients with chronic lymphatic leukemia. Leuk Lymphoma 1994; 13: 323-331.
151. Rietmüller C, Schrieider-Gädicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993; 5: 732-739.
152. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993; 14: 243-246.